Approved Study Database
Ref. No. | Scientific Title | Principal investigator |
---|---|---|
2021.699 | Photobiomodulation for Traumatic Brain Injury |
Prof. CHAN Agnes Sui Yin 陳瑞燕 |
2023.441 | Photobiomodulation for Older Adults with Mild Cognitive Impairment with and without Depression | Prof. CHAN Agnes Sui Yin |
2022.669 | Photobiomodulation for enhancing cognitive efficiency in adults |
Mr. LEE Tsz Lok 李子樂 |
2023.454 | Phono-articulatory Diadochokinesis and Test of Masticating and Swallowing Solids (TOMASS) in Healthy Individuals | Dr. FONG Raymond |
2024.009 | Phenotypic landscape and genotype correlations in patients with SCN1A mutation | Dr Yau Lo Yee |
2022.581 | Phenotypic characterization and prediction value of endometrial NK cell subsets during the window of implantation in women with repeated implantation failure | Prof. ZHANG Tao |
2012.083 | Phenotypic and functional characterization of stromal CD8+ regulatory T lymphocytes in ovarian cancer | Dr. Kwong Joseph |
2002.171 | Phase IV, A 24-weeks Prospective, Multicentre, Randomised, Double-blind, Placebo-controlled Study of Dysport Injection for the Treatment of Upper Limb Spasticity in Early Stroke | Prof. Mok C.T. Vincent |
2019.259 | Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1) |
Dr. CHAN Stephen Lam 陳林醫生 |
2004.447 | Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine (SR259075) Versus Concomitant Radiation and Cisplatin in Patients with Advanced Head and Neck Cancer | Prof. Chan Anthony |
2010.247 | Phase III Protocol Comparing a Microfracture Treatment to a Cartipatch_ Chondrocyte Graft Treatment in Femoral Condyle Lesions | Professor Chan Kai Ming |
2010.366 | Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) versus Sorafenib in Locally Advanced Hepatocellular Carcinoma | |
2008.056 | Phase IIb/III Randomized, Double-Blind Trial of BIBW 2992 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Non-Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib | Professor Mok Tony |
2020.361 | Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis B Virus (B-Clear) |
Dr. AU Kenneth Hon Da 許祖紳 |
2014.462 | Phase II Trial of the Addition of Gemcitabine to 131I-MIBG Therapy in Paediatric Patients with Relapsed or Progressive Neuroblastoma | Dr. LI Chi Kong |
2005.142 | Phase II Trial of PS-341 in Patients with Hepatocellular Carcinoma | Prof. Mok S.K. Tony |
2016.347 | Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199) |
Dr. POON Darren Ming Chun 潘明駿醫生 |
2014.477 | Phase II Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) | Dr. MOK Florence Siu Ting |
2007.096 | Phase II Trial of Gemcitabine and Cisplatin/ Carboplatin (GC) Plus Erlotinib in Patients with Recurrent And/Or Metastatic Nasopharyngeal Cancer (NPC) | Prof. Ma BY Brigette |
2012.312 | Phase II study to evaluate induction chemotherapy using docetaxel, cisplatin and fluorouracil followed by weekly docetaxel and cetuximab in concurrence with intensity-modulated radiotherapy for locally recurrent nasopharyngeal carcinoma (NPC). | Dr. LEUNG Sing Fai |
2004.125A | Phase II Study of ZD1839 (IRESSA) in Metastatic or Recurrent Nasopharyngeal Carcinoma | Prof. Chan T.C. Anthony |
2008.203 | Phase II Study of TAS-106 in Patients with Recurrent or Metastatic Head and Neck Cancer Refractory to Platinum Based Chemotherapy | Prof. Chan Anthony |
2002.111 | Phase II Study of Gemcitabine/Carboplatin Combination Chemotherapy As First Line Therapy Or Recurrent Or Metastatis Breast Cancer | Prof. Yeo Winnie |
2016.086 | Phase II Study of AZD9291 in patients with advanced stage non-small cell lung cancer following prior EGFR TKI Therapy with EGFR and T790M mutations detected in plasma circulating tumor DNA |
Prof. MOK Tony Shu Kam 莫樹錦 |
2007.445 | Phase II Study of AZD 2171 in Patients with Recurrent Small Cell Lung Cancer | Professor Mok Tony |
2011.611 | Phase II of Pilot Study of Cognitive Registry at Acute Stroke Unit at Prince of Wales Hospital | Prof. MOK Vincent Chung Tong |
2002.018 | Phase II Efficacy Study for the Emphasys Medical Bronchial Valves and Procedure | Prof. Yim P C Anthony |
2016.194 | Phase II clinical study on the safety and efficacy of Antireflux Mucosectomy (ARMS) for treatment of Gastroesophageal Reflux Disease |
Prof. CHIU Philip Wai Yan 趙偉仁 |
2017.247 | Phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
2008.395 | Phase I/II Study of Temsirolimus (Torisel) as Novel Therapeutic Drug for Patients with Unresectable Hepatocellular Carcinoma (HCC) - A Correlative Study with Stathmin Over-expression | Prof. YEO Winnie |
2007.095 | Phase I/II Study of Paclitaxel/ Carboplatin/ RAD001 as First Line Therapy for Advanced Adenocarcinoma of the Stomach | Prof. YEO Winnie |
2015.152 | Phase I/II study of aflibercept and the modified XELIRI regimen in the second-line treatment of metastatic colorectal cancer | Prof. MA Brigette |
2010.399 | Phase I, open label, randomized study to examine the pharmacokinetics, safety and tolerability of different oral doses of TMC435 after single and repeated dosing in healthy Chinese subjects | Prof. Tomlinson Brian |
2005.456 | Phase I Study on the Study and Pharmacokinetics of Single and Repeated Application of IMD-0354 in Health Male Volunteers | Prof. Brian Tomlinson |
2005.148 | Phase I Study on the Safety and Pharmacokinetics of IMD-1041 in Healthy Male Volunteers | Prof. Brian Tomlinson |
2013.638 | Phase I clinical trial on intra-operative local supplementation of vitamin C irrigation saline during anterior cruciate ligament reconstruction | Prof. YUNG Patrick Shu Hang |
2015.065 | Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis | Prof. TAM Lai Shan |
2008.364 | Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa as First-line Treatment in Subjects with Advanced Renal Cell Carcinoma | Dr. Ho Wing Ming |
2009.596 | Phase 3, Randomized, Open-label Study of the Efficacy and Safety of PF-02341066 Versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Event Involv | MOK S K Tony |
2011.217 | Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus | Prof. MOK Tony S. K. |
2012.473 | PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED EAST ASIAN PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS | Prof. MOK Tony Shu Kam |
2015.670 | Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A |
Dr. WONG Raymond Siu Ming 王紹明醫生 |
2015.631 | Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A |
Dr. LI Chi Kong 李志光醫生 |
2016.247 | Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 years with severe hemophilia A (FVIII < 1%) |
Dr. LI Chi Kong 李志光 |
2016.565 | Phase 3, Multicenter, Randomized, Double-blind, placebo-controlled, parallel-group, efficacy and safety study comparing EG-1962 to standard of care oral Nimodipine in adults with aneurysmal subarachnoid hemorrhage. |
Prof. POON Wai Sang 潘偉生 |
2023.369 | Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk | Ms. LUK Andrea On Yan |
2021.399 | PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH OR WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01) |
Dr LOONG Herbert Ho Fung 龍浩鋒 |
2022.552 | Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1) |
Prof. WONG Grace Lai Hung 黃麗虹 |
2009.638 | Phase 2, Open-label, Single Arm Study of the Efficacy and Safety of PF-02341066 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation or Inversion Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus | Prof. MOK Tony S. K. |
2024.358 | Phase 2 study on safety and efficacy of irreversible electroporation for locally advanced pancreatic malignancy | Prof. CHOK Siu Ho |
Page 76 of 254.